Company: Tasly Pharmaceutical Group Company Limited

Bloomberg ticker: 600535 SH

Market cap: US$3,339m

Background: Tasly Pharmaceutical Group Company Limited focuses on research, development, manufacturing, and marketing of modern traditional Chinese medicine (TCM) and chemical drugs. Operating primarily in China with a growing international presence, its flagship product, Dantonic, is a cardiovascular TCM drug.

World Class Benchmarking of Tasly Pharmaceutical Group

---

---

 

• Profitable Growth rank of 6 was down compared to the prior period’s 5th rank
• This is below average performance compared to 380 large Health Care companies worldwide
• Profitability rank of 5 was better than its Growth rank of 8
• Profitability rank of 5 was down compared to the prior period’s 4th rank
• This is average performance compared to peers
• Growth rank of 8 was down compared to the prior period’s 6th rank
• This is below average performance compared to peers

 

---

DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.